Compare KGC & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KGC | KVUE |
|---|---|---|
| Founded | 1993 | 2022 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Specialty Chemicals |
| Sector | Basic Materials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8B | 32.9B |
| IPO Year | 1994 | 2023 |
| Metric | KGC | KVUE |
|---|---|---|
| Price | $24.71 | $19.83 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $31.71 | $19.45 |
| AVG Volume (30 Days) | 8.4M | ★ 19.0M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | 0.45% | ★ 4.82% |
| EPS Growth | N/A | ★ 40.74 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $15,124,000,000.00 |
| Revenue This Year | $38.70 | $4.85 |
| Revenue Next Year | N/A | $2.63 |
| P/E Ratio | ★ $24.18 | $79.22 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.04 | $14.02 |
| 52 Week High | $39.11 | $22.87 |
| Indicator | KGC | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 75.51 |
| Support Level | $23.77 | $16.83 |
| Resistance Level | $28.73 | N/A |
| Average True Range (ATR) | 0.91 | 0.35 |
| MACD | -0.04 | 0.14 |
| Stochastic Oscillator | 26.71 | 98.01 |
Kinross Gold is a Canada-based gold producer, producing roughly 2 million gold equivalent ounces in 2025. The company had about a decade of gold reserves at the end of 2025. It operates mines in the Americas and West Africa after selling its low-cost Russian operations in 2022 in response to the invasion of Ukraine. Kinross has historically used acquisitions to fuel expansion into new regions and production growth. In 2022, Kinross purchased the Great Bear project in Canada. If developed as we think likely, it could produce an average of more than 500,000 ounces of gold per year for at least a decade, with its unit cash costs likely in the first quartile of the industry cost curve. Though Great Bear's production is likely to be replacement ounces for falling volumes at other mines.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.